Calgary Mind & Wellness Clinic on Facebook

Phone: 780-978-9010 

Neurofeedback for ADHD: Benefits, Durability and the Evidence Debate

by | Sep 4, 2026 | ADHD Assessment & Testing, Neurofeedback & Brain Health

Neurofeedback & qEEG Research Library

ADHD is one of the most studied applications of neurofeedback. Some meta-analyses report sustained symptom improvement, while analyses limited to probably blinded outcomes are more cautious.

Why this finding matters

Unlike a short-term coping strategy, neurofeedback is intended to help a person practise regulation over repeated sessions. Some studies found that attention benefits persisted at follow-up, although blinded ratings were more cautious.

Research Spotlight

Effects may persist after training

  • Inattention SMD 0.64 post-treatment
  • Inattention SMD 0.80 at follow-up
  • Controlled studies vary
  • Blinded ratings are more cautious

What the evidence suggests

A systematic review reported a medium within-group effect for inattention after treatment and a larger effect at follow-up. However, another meta-analysis of well-controlled trials concluded that probably blinded outcomes did not support a specific treatment effect.

What this could mean for you

This pattern supports transparent shared decision-making. Neurofeedback can be considered as part of an individualized ADHD plan, while diagnostic assessment, school or workplace supports, behavioural strategies and medication options remain important.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Could neurofeedback support your attention goals?

A consultation helps determine whether neurofeedback, an ADHD assessment or another treatment pathway best fits the difficulties you want to address.

Book a Consultation   Explore the related Calgary service

Related Calgary services: Neurofeedback Calgary · ADHD Assessment Calgary

Study citation

Van Doren et al. Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. PMID: 29445867 · DOI: 10.1007/s00787-018-1121-4.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

TMS for Binge Eating and Food Cravings: What Is Known

by | Sep 4, 2026 | EXOMIND & rTMS Research, Mental Health & Wellness

EXOMIND & rTMS Research Library

Neuromodulation research has examined food cravings and binge-eating symptoms, but current evidence is preliminary and should not be interpreted as establishing TMS as a stand-alone eating-disorder treatment.

Why this finding matters

Food cravings and binge-eating symptoms can feel difficult to control and often require coordinated psychological, medical and nutritional care. Brain-stimulation research is developing, but current findings do not justify treating TMS as a stand-alone solution.

Research Spotlight

Promising but preliminary

  • 18 systematic reviews examined
  • 5 included meta-analysis
  • RCT findings vary
  • Review quality often low

What the evidence suggests

A 2025 umbrella review included 18 systematic reviews, five with meta-analysis. Some randomized trials reported reductions in binge eating and craving, while outcomes for weight and broader eating-disorder symptoms were less consistent.

What this could mean for you

For clients reporting binge eating or loss-of-control eating, comprehensive medical and psychological assessment remains central. TMS may be discussed only as an emerging adjunct where clinically appropriate.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Begin with a responsible clinical discussion

We can review the concern, existing supports and whether another evidence-based pathway should come before—or alongside—any neuromodulation discussion.

Book a Consultation   Explore the related Calgary service

Study citation

Longo et al. Neuromodulatory techniques in eating disorders: from brain stimulation to clinical outcomes. PMID: 39740315.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

TMS for ADHD and Executive Function: Emerging Evidence Explained

by | Sep 4, 2026 | ADHD Assessment & Testing, EXOMIND & rTMS Research

EXOMIND & rTMS Research Library

Recent systematic reviews have examined transcranial magnetic stimulation for inattention, hyperactivity and impulsivity. Results are promising, but the evidence is not yet strong enough to position TMS as a first-line ADHD treatment.

Why this finding matters

Attention and executive-function difficulties can affect work, school, relationships and confidence. Early TMS findings are encouraging, but the evidence does not support replacing established ADHD assessment and treatment with brain stimulation.

Research Spotlight

Promising—not yet first-line

  • Systematic review
  • Symptom domains studied
  • Minor adverse events reported
  • More trials needed

What the evidence suggests

A 2025 systematic review and meta-analysis reported improvements across inattention, hyperactivity/impulsivity and total ADHD symptom scores, with generally minor adverse events. More recent syntheses continue to describe domain-specific potential.

What this could mean for you

For people seeking help with focus or executive functioning, neuropsychological formulation remains essential. EXOMIND may be discussed as an emerging option only after considering diagnosis, sleep, mood, medication, learning history and functional demands.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Clarify the right pathway first

We can help distinguish diagnostic assessment, standard ADHD care and an emerging brain-optimization pathway so you can make an informed decision.

Book a Consultation   Explore the related Calgary service

Related Calgary service: ADHD Assessment Calgary   EXOMIND rTMS Calgary

Study citation

Fu et al. Efficacy and safety of transcranial magnetic stimulation for attention-deficit/hyperactivity disorder: systematic review and meta-analysis. PMID: 39829146.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

rTMS for PTSD: Why the Evidence Requires Careful Interpretation

by | Sep 4, 2026 | EXOMIND & rTMS Research, Trauma Treatment

EXOMIND & rTMS Research Library

A recent systematic review found that active rTMS probably made little to no difference to PTSD severity compared with sham treatment in its primary analysis, although broader sensitivity analyses showed substantial variation across studies.

Why honest evidence matters

People living with PTSD deserve clear information, especially when a treatment is being considered. The primary analysis did not show a reliable advantage over sham treatment, so EXOMIND should not be marketed as an established PTSD treatment on the basis of this evidence.

Research Spotlight

Evidence remains uncertain

  • 3 primary-analysis studies
  • 99 participants
  • SMD −0.14
  • Protocol heterogeneity

What the evidence suggests

The primary analysis included three studies and 99 participants and produced a standardized mean difference of −0.14, with a confidence interval crossing no effect. When additional studies were included, results remained heterogeneous.

What this could mean for you

This evidence supports an assessment-first approach. rTMS may still be discussed for comorbid depression or within emerging PTSD research, but it should not be marketed as an established stand-alone PTSD treatment.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Start with clinical fit—not promises

A consultation can clarify the main treatment target, established options and whether neuromodulation has any appropriate adjunctive role.

Book a Consultation   Explore the related Calgary service

Study citation

Brown et al. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. PMID: 39092744.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

rTMS for Peripartum and Postpartum Depression: Research Summary

by | Sep 4, 2026 | Depression Treatment, EXOMIND & rTMS Research

EXOMIND & rTMS Research Library

A systematic review and meta-analysis evaluated rTMS during pregnancy and the postpartum period and reported a significant pooled therapeutic effect for depressive symptoms.

Why this finding matters

Depression during pregnancy or after birth can be serious, exhausting and difficult to treat. The pooled findings support further discussion of rTMS as a non-invasive option, while the smaller evidence base means decisions should be coordinated carefully with the person’s healthcare team.

Research Spotlight

Large pooled symptom effect

  • 11 studies reviewed
  • 5 studies in quantitative synthesis
  • SMD 1.394
  • More research required

What the evidence suggests

Eleven studies were included in the systematic review and five in the quantitative synthesis. The reported therapeutic effect size was 1.394, with a sensitivity-analysis estimate of 1.074. No severe maternal or fetal adverse effects were reported in the included studies.

What this could mean for you

The findings support further discussion of rTMS as a potential non-medication option for carefully screened peripartum or postpartum depression. Decisions require coordination with the client’s medical and perinatal care team.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Explore a carefully coordinated consultation

We can review symptoms, timing, current care and safety considerations. No treatment recommendation is made without individualized assessment.

Book a Consultation   Explore the related Calgary service

Study citation

Lee, Kim and Kwon. Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review and meta-analysis. PMID: 33563220 · DOI: 10.1186/s12884-021-03600-3.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.